On July 18, 2018, Secretary of Commerce Wilbur Ross announced the initiation of a Section 232 investigation into the impact of uranium imports on America’s national security.
Reuters reported that during the third installment of its Transforming Women’s Leadership in the Law event, Managing Partner Cristina Carvalho spoke on a Rising Stars panel “Steering A New Ship: Women’s Rise to Leadership in Law Firms.”
On Friday, July 13, 2018, the California Office of Statewide Health Planning and Development (OSHPD) posted proposed regulations implementing California’s drug price transparency law.
As the most recent state to address the issue of what to do with unused medications, on July 10, 2018, New York Governor Andrew Cuomo signed the Drug Take Back Act (the Act).
Immigration officials have been dramatically increasing inspections in California in 2018 at workplaces ranging in size from small convenience stores to large agricultural operations.
Washington — Arent Fox LLP announced today that it represented SunBridge Capital Management, LLC in its equity investment in Florida-chartered Beach Community Bank. Sunbridge is part of a group of investors that in the aggregate have recapitalized the bank with approximately $100 million.
The United States Department of Agriculture and the Food and Drug Administration have recently initiated processes to evaluate and propose revisions to their approaches to the regulation of products of agricultural biotechnology.
In November, 2016, the FTC amended the Used Car Rule, and made significant changes to the Buyers Guide. The amended Rule required dealers to begin displaying the revised Buyers Guide beginning January 28, 2018.
Arent Fox Sports Practice Group Leader Rich Brand was quoted in the Louisville Courier Journal on the forthcoming naming rights deal for the University of Louisville Cardinal Stadium.
The Clean Water Act (CWA) term “waters of the United States” (WOTUS) has become an evolving term with an often squishy definition leading to considerable litigation.
On July 11, 2018, the House Energy and Commerce Subcommittee on Communications and Technology held a hearing titled “Protecting Customer Proprietary Network Information in the Internet Age.”
Schiff Hardin is proud to announce that Intellectual Property Practice Group Co-Leader Imron Aly has been recognized in the seventh edition of IAM Patent 1000.
As citizen scientists and environmental non-governmental organizations (NGOs) have stepped up to fill what they have called an enforcement gap since President Trump took office, the NGO playbook has become more complex and creative than perhaps ever before.
The ABA Young Lawyers Division Health Law Committee and ABA Health Law Section is hosting a networking reception followed by a roundtable discussion with senior government attorneys from CMS, DOJ, and OIG.
On July 6, 2018, the implementation day for the Section 301 “List 1” duties, the United States Trade Representative released the procedures for filing exclusion requests for List 1 products subject to the 25 percent tariff pursuant to Section 301 of the Trade Act of 1974.
On June 28, 2018, the Securities and Exchange Commission (SEC) voted to amend the definition of “smaller reporting company” to allow more companies to use the scaled disclosure requirements available to smaller reporting companies.
The association between the alcohol beverage and cannabis industries continues to grow. Dan O’Neill, a former CEO of Molson Brewery and past senior executive at Campbell Soup Company and H.J. Heinz, has recently joined the board of CannaRoyalty.
Intellectual Property Group Co-Leader Imron Aly was quoted on a U.S. Supreme Court patent ruling in Oil States Energy Services LLC v. Greene’s Energy Group LLC that upheld the America Invents Act (AIA) review system for challenging patents as constitutional, with some key operation changes.
Within hours of its unanimous passing in both the California State Senate and Assembly, Governor Jerry Brown signed the strongest online privacy law in the country, the California Consumer Privacy Act of 2018.
On June 28, 2018, the Pharmaceutical Research and Manufacturers of America (PhRMA) and Biotechnology Innovation Organization (BIO) dropped their lawsuit challenging the constitutionality of Nevada’s recent drug price transparency law.